Last reviewed · How we verify

Insulin, Asp(B28)-

Oxford University Hospitals NHS Trust · FDA-approved active Small molecule

Insulin, Asp(B28)- is a Rapid-acting insulin analog Small molecule drug developed by Oxford University Hospitals NHS Trust. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: NovoRapid, NovoRapid insulin, Aspart insulin, Novolog.

Insulin Asp(B28) is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for energy and storage.

Insulin Asp(B28) is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for energy and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameInsulin, Asp(B28)-
Also known asNovoRapid, NovoRapid insulin, Aspart insulin, Novolog
SponsorOxford University Hospitals NHS Trust
Drug classRapid-acting insulin analog
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

This insulin analog has aspartic acid substituted at position B28 of the insulin B-chain, which modifies its pharmacokinetic properties compared to human insulin. It acts as an exogenous insulin replacement therapy, mimicking the body's natural insulin response by facilitating cellular glucose uptake, promoting glycogen synthesis, and inhibiting gluconeogenesis. The structural modification allows for faster absorption and onset of action compared to regular human insulin.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Insulin, Asp(B28)-

What is Insulin, Asp(B28)-?

Insulin, Asp(B28)- is a Rapid-acting insulin analog drug developed by Oxford University Hospitals NHS Trust, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

How does Insulin, Asp(B28)- work?

Insulin Asp(B28) is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for energy and storage.

What is Insulin, Asp(B28)- used for?

Insulin, Asp(B28)- is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Who makes Insulin, Asp(B28)-?

Insulin, Asp(B28)- is developed and marketed by Oxford University Hospitals NHS Trust (see full Oxford University Hospitals NHS Trust pipeline at /company/oxford-university-hospitals-nhs-trust).

Is Insulin, Asp(B28)- also known as anything else?

Insulin, Asp(B28)- is also known as NovoRapid, NovoRapid insulin, Aspart insulin, Novolog.

What drug class is Insulin, Asp(B28)- in?

Insulin, Asp(B28)- belongs to the Rapid-acting insulin analog class. See all Rapid-acting insulin analog drugs at /class/rapid-acting-insulin-analog.

What development phase is Insulin, Asp(B28)- in?

Insulin, Asp(B28)- is FDA-approved (marketed).

What are the side effects of Insulin, Asp(B28)-?

Common side effects of Insulin, Asp(B28)- include Hypoglycemia, Injection site reactions, Weight gain, Lipodystrophy.

What does Insulin, Asp(B28)- target?

Insulin, Asp(B28)- targets Insulin receptor and is a Rapid-acting insulin analog.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing